Investig Clin Urol.  2019 Nov;60(6):432-442. 10.4111/icu.2019.60.6.432.

Significant clinicopathologic prognostic factors for bladder recurrence, progression, and cancer-specific survival after surgery among patients with upper urinary tract urothelial carcinoma

• Kim SH
• Song MK
• Joung JY
• Chung J
• Lee KH
• Seo HK

• KMID: 2461054
• DOI: http://doi.org/10.4111/icu.2019.60.6.432

Abstract

PURPOSE
This study aimed to identify prognostic factors for outcomes after radical nephroureterectomy among patients with upper urinary tract urothelial carcinoma (UTUC).
MATERIALS AND METHODS
We retrospectively reviewed 184 nonmetastatic cases of UTUC after radical nephroureterectomy, bladder cuffing, and/or partial cystectomy (2004-2016). Bladder recurrence-free survival (BRFS), disease progression-free survival (DPFS), and cancer-specific survival (CSS) were estimated. The prognostic values of clinicopathologic parameters were evaluated by using Cox logistic regression analysis.
RESULTS
The median BRFS, DPFS, and CSS values were 19.0 months, 38.5 months, and 67.0 months, respectively. We identified cases of bladder recurrence (64 cases, 34.8%), disease progression (54 cases, 29.3%), and cancer-specific death (23 cases, 12.5%). BRFS was independently associated with lymphovascular invasion (hazard ratio [HR], 0.421); DPFS was associated with intravesical instillation (HR, 0.290), active smoking (HR, 0.367), synchronous bladder lesions (HR, 2.355), and pT2 (HR, 5.199) and pT3 and pT4 (HR, 13.281) stages; and CSS was associated with alkaline phosphatase levels (HR, 0.966). Among 123 cases without previous bladder cancer, DPFS was associated with intravesical instillation (HR, 0.264), multifocal ureteral tumors (HR, 4.823), and pT3 and pT4 stages (HR, 10.899), whereas CSS was associated with pTis (HR, 32.071).
CONCLUSIONS
Patients with the factors we identified should receive adjuvant intravesical/systemic chemotherapy and intensive surveillance.

Keyword

Nephroureterectomy; Prognosis; Risk factors; Survival; Ureteral neoplasms

MeSH Terms

Administration, Intravesical
Alkaline Phosphatase
Cystectomy
Disease Progression
Disease-Free Survival
Drug Therapy
Humans
Logistic Models
Prognosis
Recurrence*
Retrospective Studies
Risk Factors
Smoke
Smoking
Ureter
Ureteral Neoplasms
Urinary Bladder Neoplasms
Urinary Bladder*
Urinary Tract*
Alkaline Phosphatase
Smoke

Reference

1. Lehmann J, Suttmann H, Kovac I, Hack M, Kamradt J, Siemer S, et al. Transitional cell carcinoma of the ureter: prognostic factors influencing progression and survival. Eur Urol. 2007; 51:1281–1288. PMID: 17125909.

2. Liang C, Chi R, Huang L, Wang J, Liu H, Xu D, et al. Upper tract urothelial carcinomas accompanied by previous or synchronous nonmuscle-invasive bladder cancer and preoperative hydronephrosis might have worse oncologic outcomes after radical nephroureterectomy. Clin Genitourin Cancer. 2016; 14:e469–e477. PMID: 27021588.

3. Raman JD, Scherr DS. Management of patients with upper urinary tract transitional cell carcinoma. Nat Clin Pract Urol. 2007; 4:432–443. PMID: 17673914.

4. Margulis V, Shariat SF, Matin SF, Kamat AM, Zigeuner R, Kikuchi E, et al. the Upper Tract Urothelial Carcinoma Collaboration. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer. 2009; 115:1224–1233. PMID: 19156917.

5. Verhoest G, Shariat SF, Chromecki TF, Raman JD, Margulis V, Novara G, et al. Predictive factors of recurrence and survival of upper tract urothelial carcinomas. World J Urol. 2011; 29:495–501. PMID: 21681525.

6. Rouprêt M, Babjuk M, Compérat E, Zigeuner R, Sylvester RJ, Burger M, et al. European Association of Urology guidelines on upper urinary tract urothelial cell carcinoma: 2015 update. Eur Urol. 2015; 68:868–879. PMID: 26188393.

7. Cha EK, Shariat SF, Kormaksson M, Novara G, Chromecki TF, Scherr DS, et al. Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. Eur Urol. 2012; 61:818–825. PMID: 22284969.

8. Morizane S, Yumioka T, Yamaguchi N, Masago T, Honda M, Sejima T, et al. Risk stratification model, including preoperative serum C-reactive protein and estimated glomerular filtration rate levels, in patients with upper urinary tract urothelial carcinoma undergoing radical nephroureterectomy. Int Urol Nephrol. 2015; 47:1335–1341. PMID: 26104379.

9. Yates DR, Hupertan V, Colin P, Ouzzane A, Descazeaud A, Long JA, et al. French collaborative national database on UUT-UC. Cancer-specific survival after radical nephroureterectomy for upper urinary tract urothelial carcinoma: proposal and multi-institutional validation of a post-operative nomogram. Br J Cancer. 2012; 106:1083–1088. PMID: 22374463.

10. Cho KS, Hong SJ, Cho NH, Choi YD. Grade of hydronephrosis and tumor diameter as preoperative prognostic factors in ureteral transitional cell carcinoma. Urology. 2007; 70:662–666. PMID: 17991533.

11. Chung PH, Krabbe LM, Darwish OM, Westerman ME, Bagrodia A, Gayed BA, et al. Degree of hydronephrosis predicts adverse pathological features and worse oncologic outcomes in patients with high-grade urothelial carcinoma of the upper urinary tract. Urol Oncol. 2014; 32:981–988. PMID: 25022858.

12. Hwang I, Jung SI, Nam DH, Hwang EC, Kang TW, Kwon DD, et al. Preoperative hydronephrosis and diabetes mellitus predict poor prognosis in upper urinary tract urothelial carcinoma. Can Urol Assoc J. 2013; 7:E215–E220. PMID: 23671529.

13. Zhang X, Zhu Z, Zhong S, Xu T, Shen Z. Ureteral tumours showing a worse prognosis than renal pelvis tumours may be attributed to ureteral tumours more likely to have hydronephrosis and less likely to have haematuria. World J Urol. 2013; 31:155–160. PMID: 22614444.

14. Li CC, Chang TH, Wu WJ, Ke HL, Huang SP, Tsai PC, et al. Significant predictive factors for prognosis of primary upper urinary tract cancer after radical nephroureterectomy in Taiwanese patients. Eur Urol. 2008; 54:1127–1134. PMID: 18243511.

15. Kim BW, Ha YS, Lee JN, Kim HT, Kim TH, Lee JK, et al. Effects of previous or synchronous non-muscle invasive bladder cancer on clinical results after radical nephroureterectomy for upper tract urothelial carcinoma: a multi-institutional study. Urol J. 2015; 12:2233–2239. PMID: 26341764.

16. Favaretto RL, Shariat SF, Chade DC, Godoy G, Adamy A, Kaag M, et al. The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center. Eur Urol. 2010; 58:574–580. PMID: 20637540.

17. Otto W, Shariat SF, Fritsche HM, Gupta A, Matsumoto K, Kassouf W, et al. Concomitant carcinoma in situ as an independent prognostic parameter for recurrence and survival in upper tract urothelial carcinoma: a multicenter analysis of 772 patients. World J Urol. 2011; 29:487–494. PMID: 21249372.

18. Xylinas E, Kluth LA, Rieken M, Lee RK, Elghouayel M, Ficarra V, et al. UTUC Collaboration. Impact of smoking status and cumulative exposure on intravesical recurrence of upper tract urothelial carcinoma after radical nephroureterectomy. BJU Int. 2014; 114:56–61. PMID: 24053463.

19. Nuhn P, Novara G, Seitz C, Gupta A, Matsumoto K, Kassouf W, et al. Prognostic value of prior history of urothelial carcinoma of the bladder in patients with upper urinary tract urothelial carcinoma: results from a retrospective multicenter study. World J Urol. 2015; 33:1005–1013. PMID: 25048439.

20. Hall MC, Womack S, Sagalowsky AI, Carmody T, Erickstad MD, Roehrborn CG. Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology. 1998; 52:594–601. PMID: 9763077.

21. Pignot G, Colin P, Zerbib M, Audenet F, Soulié M, Hurel S, et al. French Collaborative National Database on UUT-UC. Influence of previous or synchronous bladder cancer on oncologic outcomes after radical nephroureterectomy for upper urinary tract urothelial carcinoma. Urol Oncol. 2014; 32:23.e1–23.e8.

22. Mathieu R, Bensalah K, Lucca I, Mbeutcha A, Rouprêt M, Shariat SF. Upper urinary tract disease: what we know today and unmet needs. Transl Androl Urol. 2015; 4:261–272. PMID: 26816829.

23. Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. JAMA. 2011; 306:737–745. PMID: 21846855.

24. Crivelli JJ, Xylinas E, Kluth LA, Rieken M, Rink M, Shariat SF. Effect of smoking on outcomes of urothelial carcinoma: a systematic review of the literature. Eur Urol. 2014; 65:742–754. PMID: 23810104.

25. Jensen OM, Knudsen JB, McLaughlin JK, Sørensen BL. The Copenhagen case-control study of renal pelvis and ureter cancer: role of smoking and occupational exposures. Int J Cancer. 1988; 41:557–561. PMID: 3356489.

26. Rink M, Xylinas E, Margulis V, Cha EK, Ehdaie B, Raman JD, et al. Upper Tract Urothelial Carcinoma Collaboration. Impact of smoking on oncologic outcomes of upper tract urothelial carcinoma after radical nephroureterectomy. Eur Urol. 2013; 63:1082–1090. PMID: 22743166.

27. Hurel S, Rouprêt M, Ouzzane A, Rozet F, Xylinas E, Zerbib M, et al. French Collaborative National Database on UTUC. Impact of lymphovascular invasion on oncological outcomes in patients with upper tract urothelial carcinoma after radical nephroureterectomy. BJU Int. 2013; 111:1199–1207. PMID: 23650914.

28. Ouzzane A, Colin P, Xylinas E, Pignot G, Ariane MM, Saint F, et al. French Collaborative National Database on UUT-UC. Ureteral and multifocal tumours have worse prognosis than renal pelvic tumours in urothelial carcinoma of the upper urinary tract treated by nephroureterectomy. Eur Urol. 2011; 60:1258–1265. PMID: 21665356.

29. Dabare AA, Nouri AM, Cannell H, Moss T, Nigam AK, Oliver RT. Profile of placental alkaline phosphatase expression in human malignancies: effect of tumour cell activation on alkaline phosphatase expression. Urol Int. 1999; 63:168–174. PMID: 10738188.